Conduit Pharmaceuticals Files VTAMA Cocrystal Patent with Eye on Anti-Inflammatory Market
DENVER, Colo., Apr 11, 2025 (247marketnews.com)- Conduit Pharmaceuticals (NASDAQ:CDT) submitted two cocrystal patent filings for VTAMA (tapinarof), turbocharging its blockbuster potential ahead of a 2027 exclusivity cliff. This next-gen tapinarof, a dual-active marvel pairing the psoriasis and atopic dermatitis champ with a sidekick drug, could blast past generics, eyeing the anti-inflammatory.
Dr. Joanne Holland, Conduit’s Chief Scientific Officer, stated, “With this strategic addition to our portfolio, we are not just adding another asset, but adding what we believe to be a highly commercially valuable patent position for tapinarof. Whilst the current formulation is focused purely on underlying disease, our tapinarof cocrystal aims to offer a multifaceted approach addressing patient symptoms as well as disease. New composition of matter IP, on a drug that could imminently face generic competition on near-term exclusivity expiry, could offer partners a strong position to exploit its market potential in the wider inflammatory and autoimmune space. We are now actively pursuing partnerships that can leverage this breakthrough IP while we continue to advance our broader pipeline.”
VTAMA, nabbed by Organon for $1.2 billion from Dermavant, gets a boost with this cocrystal innovation, tackling pain and itch alongside inflammation.
With generics looming in 2027, this patent filing blends improved tolerability, extended protection, and expanded uses, to position CDT for juicy licensing deals in a $94 billion dermatology boom.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com